Bibliografia

GESTIONE
  1. Global Initiative for Asthma. Global strategy for Asthma management and prevention, 2018.
COS'È L'ASMA GRAVE
  1. Global Initiative for Asthma. Global strategy for Asthma management and prevention, 2018.
  2. von Bülow A et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2(6):759-67.
  3. Nunes C et al. Asthma costs and social impact. Asthma Res Pract. 2017 Jan 6;3:1.
  4. My life with asthma Survey. aafa.org
  5. Paggiaro P e gruppo GINA Italia. Linee guida GINA italiane. Versione 2016 – 2017.
  6. Di Marco F et al. Close correlation between anxiety, depression, and asthma control. Respir Med. 2010;104(1):22-8.
  7. Dal Negro RW et al. Cost of persistent asthma in Italy. Multidiscip Respir Med. 2016;11:44.
  8. Zeiger RS et al. J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):120-9.e3.
  9. Sweeney J, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71(4):339-46.
COSA DICE LA SCIENZA?
  1. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
  2. Global Initiative for Asthma. Global strategy for Asthma management and prevention, 2018.
  3. Peters MC et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014;133(2):388-394.
  4. Fahy et al. Type 2 inflammation in asthma — present in most, absent in many. Nat Rev Immunol 2015 Jan;15(1):57-65.
  5. Dunican EM, Fahy JV. The Role of Type 2 Inflammation in the Pathogenesis of Asthma Exacerbations. Ann Am Thorac Soc 2015;12 Suppl 2:S144–S149.
  6. Muraro A et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2016;137(5):1347-58.
COMORBIDITÀ
  1. Fahy et al. Type 2 inflammation in asthma-present in most, absent in many. Nat Rev Immunol 2015 Jan;15(1):57-65.
  2. Global Initiative for Asthma. Global strategy for Asthma management and prevention, 2018.
  3. Heffler E et al. The Severe Asthma Network in Italy: Findings and Perspectives. J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1462-1468.
  4. Langdon C, Mullol J. Nasal polyps in patients with asthma: prevalence, impact, and management challenges. J Asthma Allergy 2016;9:45-53.
  5. Kato A. Immunopathology of chronic rhinosinusitis. Allergol Int. 2015 Apr;64(2):121-30.
  6. Schleimer RP. Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis. Annu Rev Pathol. 2017;12:331-357.
  7. Bachert C et al. ICON: chronic rhinosinusitis. World Allergy Organ J 2014;7(1):25.
  8. Dietz de Loos DA, et al. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013 Jan;123(1):57-63.
  9. Corren J et al. Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. J Allergy Clin Immunol Pract. 2020 Feb;8(2):516-526.
  10. Gandhi NA et al. Targeting key proximal drivers of type 2 inflammation in disease Nat Rev Drug Discov 2016;15(1):35-50.
  11. Khan A et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42.
  12. Gelmetti C et al. Dermatite Atopica 2016-2017. SIDeMaST.